% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Lfling:303217,
      author       = {L. L. Löfling and N. C. Støer and E. Botteri and R.
                      Turzanski-Fortner$^*$},
      title        = {{S}tatins and the risk of gynecological cancer: a
                      {N}orwegian population-based cohort study.},
      journal      = {International journal of epidemiology},
      volume       = {54},
      number       = {4},
      issn         = {0300-5771},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {DKFZ-2025-01568},
      pages        = {dyaf133},
      year         = {2025},
      note         = {#LA:C180# / Division of Cancer Epidemiology, German Cancer
                      Research Center, Heidelberg, Germany},
      abstract     = {Endometrial, ovarian, and cervical cancers are the most
                      common gynecological cancers, with 1.4 million diagnoses
                      worldwide in 2022. Statins are widely used for
                      cardiovascular conditions and have been studied for their
                      association with gynecological cancer risk, but results to
                      date have been inconclusive.We conducted a population-based
                      cohort study including data from the Norwegian Prescription
                      Database and the Cancer Registry of Norway, and followed
                      women aged ≥50 years from 2004 to 2018. We examined the
                      association between statin use overall and by type
                      (lipophilic, hydrophilic), and the risk of endometrial,
                      ovarian, and cervical cancers overall and by age groups and
                      histologic subgroup using Cox proportional hazard models.The
                      cohort study included 1 083 629 women. During a median
                      follow-up of 11.6 years, 334 582 $(31\%)$ used statins at
                      least once. There were 7709 cases of endometrial, 4415 cases
                      of ovarian, and 1603 cases of cervical cancers. Statin use
                      was associated with reduced risk of endometrial cancer
                      [current use hazard ratio (HR) = 0.90, $95\%$ confidence
                      interval (CI): 0.85-0.96; past use HR = 0.79, $95\%$ CI:
                      0.71-0.88]; associations were observed only for the
                      lipophilic statins, and with similar associations by age
                      groups and for type I and II endometrial cancer. No
                      consistent associations were found for ovarian or cervical
                      cancers. We found no trends for cumulative defined daily
                      doses of current use or time since cessation for any cancer
                      type.Statin use was associated with a reduced risk of
                      endometrial cancer but not with the risk of ovarian cancer
                      or cervical cancer.},
      keywords     = {Humans / Female / Norway: epidemiology /
                      Hydroxymethylglutaryl-CoA Reductase Inhibitors: therapeutic
                      use / Middle Aged / Aged / Uterine Cervical Neoplasms:
                      epidemiology / Ovarian Neoplasms: epidemiology / Ovarian
                      Neoplasms: prevention $\&$ control / Endometrial Neoplasms:
                      epidemiology / Endometrial Neoplasms: prevention $\&$
                      control / Proportional Hazards Models / Cohort Studies /
                      Registries / Risk Factors / Genital Neoplasms, Female:
                      epidemiology / cohort (Other) / gynecological cancers
                      (Other) / population-based (Other) / risk (Other) / statins
                      (Other) / Hydroxymethylglutaryl-CoA Reductase Inhibitors
                      (NLM Chemicals)},
      cin          = {C180},
      ddc          = {610},
      cid          = {I:(DE-He78)C180-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40714826},
      pmc          = {pmc:PMC12296387},
      doi          = {10.1093/ije/dyaf133},
      url          = {https://inrepo02.dkfz.de/record/303217},
}